Media Coverage · February 1, 2015
LABIOTECH.fr: Acticor Biotech wins its crowdfunding bet!
Acticor Biotech réussi le pari du crowdfunding!
By Joachim – Published on January 29, 2015 | LABIOTECH.fr
Read in English : Biotech’s crowdfunding: is France top of the class?
In France, you can feel a real enthousiasme for crowdfunding and many projects are running on different platforms. I met several companies currently fundraising to understand their reasons and issues. The first of these, Acticor Biotech, develops an antibody inhibitor of arterial thrombosis, directed against the glycoprotein 6 (GP6), a new therapeutic target on the surface of platelets.[…]
Read next in 'Media Coverage'
- Acticor relève 7 millions pour s'attaquer à l'AVC ischémique aigu
- Acticor Biotech porte sa série B à 22,3 M€
- 7 millions pour s’attaquer à l’AVC ischémique aigu
- Acticor Biotech partenaire du consortium BOOSTER dédié à la prise en charge et aux nouveaux traitements des AVC
- ACT017 : un fragment d’anticorps dont l’ACTion antithrombotique est prometteuse !